

1 **Title:**

2 **Phenotypes of cough in children: a latent class analysis**

3

4 **Authors:**

5 Maria Christina Mallet^{1,2}, Eva SL Pedersen¹, Ronny Makhoul^{1,2}, Sylvain Blanchon³, Karin Hoyler⁴, Anja
6 Jochmann⁵, Philipp Latzin⁶, Alexander Moeller⁷, Nicolas Regamey⁸, SPAC Study Team⁹, Myrofora
7 Goutaki^{1,6}, Ben D Spycher¹, Claudia E Kuehni^{1,6}

8

9 **Affiliations**

- 10 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
11 2. Graduate School for Health Sciences, University of Bern, Bern, Switzerland
12 3. Dept Woman-Mother-Child, Service of Pediatrics, Pediatric Pulmonology and Cystic Fibrosis
13 Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
14 4. Kinderpneumologie Horgen, Private Practice for Pediatric Pneumology, Horgen, Switzerland
15 5. Department of Paediatric Pulmonology, University Children's Hospital Basel, Switzerland
16 6. Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics,
17 Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
18 7. Department of Respiratory Medicine, University Children's Hospital Zurich and Children's
19 Research Centre, University of Zurich, Zurich, Switzerland
20 8. Division of Paediatric Pulmonology, Children's Hospital, Cantonal Hospital Lucerne,
21 Switzerland
22 9. A list of the SPAC Study Team can be found in the acknowledgements section

23

24 **Corresponding author:** Prof. Dr. med Claudia E. Kuehni, Institute of Social and Preventive Medicine,
25 University of Bern, Mittelstrasse 43, 3012, Bern, Switzerland; Tel: +41 31 684 35 07; email:
26 claudia.kuehni@ispm.unibe.ch

27

28

29 **Manuscript:** Words: 3440 /3500; Printed figures and tables: 7/8; Supplementary display items: 8

30 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Key words**

32 allergy, childhood, clinical phenotypes, cough, latent class analysis, FeNO, respiratory

33 symptoms, spirometry, unsupervised learning

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59 **ABSTRACT (299/300 words)**

60 **Background:** Distinguishing phenotypes among children with cough helps understand
61 underlying causes. Using a statistical data-driven approach, we identified cough phenotypes
62 and we aimed to validate them based on measurable traits, physician diagnoses, and
63 prognosis.

64 **Methods:** We used data from 531 children aged 5–16 years from the Swiss Paediatric
65 Airway Cohort—a multicentre clinical cohort of children seen in outpatient clinics since
66 2017. We included children with any parent-reported cough (i.e. cough without a cold,
67 cough at night, cough more than others, or cough longer than 4 weeks) without current
68 wheeze. We applied latent class analysis to identify phenotypes using 9 symptoms and
69 characteristics and selected the best model using the Akaike Information Criterion. We
70 assigned children to the most likely phenotype and compared the resulting groups with
71 regards to parental history, comorbidities, measurable traits, physician diagnoses, and
72 prognosis after 1 year.

73 **Results:** Our analysis distinguished 4 cough phenotypes: 1. unspecific dry cough (25%); 2.
74 non-allergic infectious and night cough with snoring and otitis (4%); 3. allergic dry night
75 cough with snoring (9%); and 4. allergic cough (61%). Children with the allergic phenotype
76 often had family or personal history of atopy and were diagnosed with asthma. Fractional
77 exhaled nitric oxide was highest for the allergic phenotype [median 17.9 parts per billion
78 (ppb)] and lowest for the non-allergic infectious phenotype (median 7.0 ppb). Positive
79 allergy test results differed across phenotypes ($p < 0.001$) and were most common among the
80 allergic (70%) and least common among the unspecific dry cough (31%) phenotypes.

81 Subsequent wheeze was thrice as high among the allergic than the unspecific dry cough
82 phenotype.

83 **Conclusion:** We distinguished 4 clinically-relevant cough phenotypes; they differed by
84 measurable traits, physician diagnoses, and prognosis. Although we excluded children with
85 current wheeze, most children belonged to allergy-related phenotypes and possibly need
86 allergy and asthma work-ups.

87 **Three key messages**

88 1. Latent class analysis identified 4 cough phenotypes distinguished by measurable
89 traits, diagnoses, and prognosis.

90

91 2. Most children belonged to allergy-related phenotypes and possibly need allergy and
92 asthma work-ups.

93

94 3. Symptom-based cough phenotypes correlate with measurable traits and potentially
95 apply to all healthcare settings.

96

97 **1. INTRODUCTION**

98 Recurrent cough is a frequent symptom in paediatric care and the underlying aetiologies are
99 heterogeneous.^[1-3] Most common causes of cough include respiratory tract infections and
100 asthma, yet many children cough in the absence of wheeze, colds, or obvious underlying
101 disease, which presents diagnostic challenges for physicians.^[1, 3-5] Many causes have been
102 described for the latter group of children, ranging from upper airway cough syndrome
103 caused by allergic and non-allergic rhinitis, asthma-like conditions and gastroesophageal
104 reflux to psychogenic and habit/tic cough disorders.^[1, 6-10] Clinical guidelines for differential
105 diagnosis of cough among children are used to classify cough into aetiologies based on
106 cough duration, dry versus wet cough, triggers, associated symptoms and diseases, and
107 measurable physiological traits, such as lung function and allergy tests. These guidelines are
108 usually based on expert opinions and involve some degree of overlap between diagnoses.<sup>[11-
109 13]</sup> Unsupervised learning methods, such as latent class analysis (LCA), are increasingly being
110 used as a more objective, data-driven approach to distinguish phenotypes of disease. Such
111 methods are not limited by predefined categories and account for multiple disease
112 dimensions.^[14, 15] Distinguishing phenotypes may lead to new hypotheses concerning
113 underlying aetiologies and mechanisms, ease diagnostic work-ups, guide targeted
114 management, and predict outcomes, such as respiratory symptoms.^[15-17]

115 Although LCA is widely used to classify children with wheeze, asthma, or bronchiolitis,^[18-25]
116 few have applied LCA to children presenting with recurrent cough.^[15, 26-28] Present studies
117 were population-based, thus mainly included children with rather mild disease, many of
118 whom had not seen a paediatric respiratory specialist for cough. In addition, most studies
119 were either focused on asthma and wheeze with little emphasis on cough—thus limiting
120 identification of cough phenotypes^[15, 26, 27]—or included measurable physiological traits for

121 phenotype definition, which limits use across healthcare settings with restricted or no
122 access to diagnostic tests.^[15, 26] We aimed to identify phenotypes of cough in children
123 consulting physicians, using information that is readily available in all healthcare settings,
124 including primary care. Using data from a clinical population of children presenting with
125 cough without current wheeze, we applied LCA to a set of cough-related symptoms and
126 characteristics to identify and describe cough phenotypes. We further aimed to validate the
127 identified phenotypes by assessing their associations with clinically-relevant features,
128 including parent-reported information, paediatric pulmonologist diagnoses, measurable
129 physiological traits, and prognosis of respiratory symptoms 1 year later.

130 **2. METHODS**

131 **2.1 Study design and population**

132 The Swiss Paediatric Airway Cohort (SPAC) is a prospective clinical study integrated into the
133 routine care of 8 paediatric respiratory outpatient clinics and 2 paediatric practices across
134 Switzerland. SPAC design and methods are described in detail elsewhere.^[29] SPAC enrolls
135 children aged 0–16 years referred by general practitioners or paediatricians for the
136 evaluation of common respiratory problems, such as cough, wheeze, and exercise-induced
137 symptoms. At time of referral, parents or guardians complete a baseline questionnaire
138 about respiratory symptoms, socio-demographic information, environmental exposures,
139 personal and family history, and comorbidities. One year after completing the baseline
140 questionnaire and yearly thereafter, parents receive a follow-up questionnaire asking about
141 symptoms and treatments during the past 12 months. From hospital records, we retrieve
142 information about results of diagnostic tests and paediatric pulmonologist diagnoses. The
143 Bern Cantonal Ethics Committee (Kantonale Ethikkommission Bern 2016-02176) approved the
144 study; parents and patients older than 14 years provided their written consent.

145 **2.2 Inclusion criteria**

146 We only included children aged 5–16 years at the time of visit because physiological traits,
147 such as lung function and allergies, are routinely measured for this age group. We included
148 all children with completed baseline parental questionnaires by December 31, 2020 who
149 indicated suffering from any recurrent cough. We used 4 validated and commonly used
150 questions about cough: “Does your child have a cough even without having a cold?” (cough
151 without a cold);^[30] “In the last 12 months has your child had a dry cough at night, apart from
152 a cough associated with a cold or a chest infection?” (dry night cough);^[31] “Do you think
153 your child coughs more than other children?” (cough more than others);^[32] and “Has your
154 child had a cough in the past 12 months that lasted more than 4 weeks in a row?” (chronic
155 cough). We excluded children who reported wheeze in the past 12 months (current
156 wheeze), but not those who reported wheeze earlier in life (> 12 months ago) or with
157 physician-diagnosed asthma earlier in life.

158 **2.3 Definition of indicator variables**

159 As indicator variables for the latent class model, we included the following 9 variables, all
160 reported during the last 12 months from the baseline questionnaire: frequency of colds (\geq
161 7/year), pneumonia, otitis media, regular snoring, rhino-conjunctivitis, dry night cough, type
162 of cough (dry versus wet), duration of cough (> 2 months), and number of allergic cough
163 triggers, including pets, pollen, and house dust, ranging from 0 to 3 (Table S1). We selected
164 these cough-related symptoms and characteristics based on a consensus among authors as
165 they were considered to be potential indicators of underlying aetiologies that can be easily
166 asked in all clinical settings, including primary care.

167

168

169 **2.4 Definition of variables to characterise and validate identified phenotypes**

170 We characterised and validated the identified phenotypes by comparing how these differed

171 according to a) parent-reported information, b) paediatric pulmonologist diagnoses, c)

172 results of measurable traits, and d) prognosis of respiratory symptoms 1 year later.

173 First, we compared the phenotypes with respect to exposure, family history, and

174 comorbidity information reported by parents in the baseline questionnaire. Second, we

175 compared the phenotypes with diagnoses given by paediatric pulmonologists who were

176 unaware of the LCA results. For simplicity, we grouped diagnoses into broad categories—

177 asthma, chronic cough, allergies, and others. A child could have several diagnoses. Appendix

178 S1 provides details of parent-reported information and physician diagnoses.

179 Third, we validated the identified phenotypes against measurable traits. We used body mass

180 index (BMI), spirometry, bronchodilator response (BDR), fractional exhaled nitric oxide

181 (FeNO), and allergy tests [skin prick test (SPT) and allergen specific IgE (sIgE)]. We converted

182 BMI into z-scores using reference values from the World Health Organisation.^[33] For

183 spirometry, we transformed forced vital capacity (FVC), forced expiratory volume in the first

184 second (FEV1), FEV1/FVC, and the forced expiratory flow between the 25% and 75% of the

185 FVC (FEF 25–75) into z-scores using the Global Lung Initiative reference values.^[34] We

186 defined a positive BDR test as an increase in FEV1 \geq 12% (from baseline FEV1) after the use

187 of a short acting beta-agonist. FeNO measurements differed across clinics, with cut-offs

188 varying from 10 parts per billion (ppb) when using an offline method to 20–25 ppb for

189 online methods.^[35] Thus, we first distinguished low versus high FeNO based on specified cut-

190 offs for each centre. We also assessed FeNO (measured online) as a continuous variable and

191 expressed in ppb. A positive allergy test was defined as either a positive SPT (mean wheal

192 size of \geq 3mm) or a positive sIgE with values \geq 0.35 kU/L. Since SPAC is an observational

193 study, physiological measurements are performed based on local protocols and indications
194 and not for all children. However, availability of measurements did not differ across
195 phenotypes (Table S2).

196 Fourth, we compared prognosis 1 year later between phenotypes by looking at reported
197 cough without a cold, dry night cough, cough more than others, cough more than 4 weeks,
198 and wheeze during the past 12 months. Parents of 360 (68%) children completed the first
199 year follow-up questionnaire and response rates did not differ by phenotype (Table S2).

200 **2.5 Statistical analysis**

201 To identify different phenotypes of cough, we fitted latent class models to the dataset
202 including the selected cough-related variables. To select number of latent classes
203 (interpreted here as phenotypes), we repeatedly fitted the model with the number of
204 classes increasing stepwise from 2 to 10 and used Bayesian Information Criterion (BIC) and
205 Akaike Information Criterion (AIC) to select the optimal model.^[36] These criteria favour
206 models that are parsimonious, i.e. have few model parameters (in our context this means
207 fewer classes), while still achieving good model fit. For the final selection, we also took into
208 account interpretability and clinical relevance. We fitted models using the generalised
209 structural equation modelling function (gsem) in STATA. The dichotomised symptom
210 variables were assumed to be binomially distributed within classes and the number of
211 allergic triggers as Poisson distributed.

212 For validation of phenotypes, we first assigned each individual to the phenotypes for which
213 it had the highest posterior membership probability.^[14] We then compared the resulting
214 groups with respect to parent-reported characteristics, paediatric pulmonologists diagnoses,
215 measured traits and prognosis of respiratory symptoms after 1 year. We tested differences

216 between phenotypes using chi-squared and Fisher exact tests for categorical variables. For
217 non-normally distributed continuous variables we used Kruskal –Wallis tests.
218 We recoded missing values for questions about symptoms as “no” since we assumed absent
219 or mild symptoms when parents have not answered “yes” (Table S1). We performed all
220 analyses in STATA (Version 15.1, StataCorp, TX, USA).

221 **3. RESULTS**

222 **3.1 Characteristics of study population**

223 Our analysis included 531 children with median age 11 years (interquartile range 8–13)
224 (Figure S1, Table 1). Parents of 446 (84%) children reported cough without a cold, 289 (54%)
225 cough more than others, 276 (52%) dry night cough, and 215 (40%) cough more than 4
226 weeks.

227 **3.2 Description of phenotypes**

228 Results of BIC and AIC were discordant: the lowest BIC indicated a model with 2 phenotypes
229 and the lowest AIC a model with 4 phenotypes (Table S3). Since identifying cough
230 phenotypes using LCA is exploratory, we present the model with 4 phenotypes which we
231 think is more clinically-relevant, assuming there are more than 2 underlying causes for
232 recurrent cough among children^[13]. We summarise class size, main characteristics, and
233 summary labels of the 4 phenotypes in the textbox, Figure 1, and Table S4.

4 cough phenotypes identified by latent class analysis (Details in Table S4)

Phenotype 1: Unspecific dry cough (25%)

Children belonging to this phenotype reported few respiratory infections or allergic symptoms. Cough was described as mostly dry for half of the children without any other distinct characteristics.

Phenotype 2: Non-allergic infectious and night cough with snoring and otitis (4%)

Frequent colds and pneumonia were more frequently reported than in other phenotypes. Children in this phenotype typically reported otitis media, night cough, and snoring. None had rhino-conjunctivitis, hardly any reported allergic triggers for cough, and cough was rarely reported as dry.

Phenotype 3: Allergic dry night cough with snoring (9%)

Night cough, snoring, dry cough, and cough lasting more than two consecutive months were typical for this phenotype. Rhino-conjunctivitis and allergic cough triggers were much more commonly reported compared with phenotypes 1 and 2.

Phenotype 4: Allergic cough (61%)

Nearly two-thirds of children were in this phenotype with highest probabilities of rhino-conjunctivitis and highest mean number of reported allergic triggers for cough. Very few colds, pneumonia, or otitis media were reported. The probability of reporting night cough and snoring was half of phenotype 3.

235 For completeness, we also present the model with 2 phenotypes in Table S5; it identified a
236 larger phenotype (73% of children) with allergic features (rhino-conjunctivitis, allergic
237 triggers), as the four-class model, and a smaller, less specific phenotype.

238 **3.3 Validation of identified phenotypes**

239 Parent-reported characteristics, paediatric pulmonologist diagnoses, measurable traits, and
240 respiratory prognosis varied between the different phenotypes. Children with phenotype 2
241 were more often male (72%) and younger (median age: 7 years) compared with other
242 phenotypes (Table 2). Family history of asthma and hay fever and atopy-related
243 comorbidities, such as previous wheeze, physician-diagnosed asthma, hay fever, and
244 eczema, were reported for all phenotypes but were most common among children with
245 phenotype 4 (allergic cough).

246 Paediatric pulmonologist diagnoses differed across the 4 phenotypes (Table 3). Asthma
247 diagnosis was most frequent in phenotype 4 (48%), followed by phenotype 1 (26%),
248 phenotype 3 (20%), and phenotype 2 (6%). Phenotype 3 contained the highest proportion of
249 children with a specific cough diagnosis (33%) by a paediatric pulmonologist, whilst in
250 phenotype 4 this number was smallest (8%). Children with phenotype 4 more often received
251 a diagnosis of rhinitis/rhino-conjunctivitis and allergic sensitisation/atopy.

252 Regarding measurable traits, BMI did not differ across the 4 phenotypes ($p=0.161$) (Table 4).
253 Median z-scores of spirometry parameters (FCV, FEV1/FVC, and FEF25-75) were lowest for
254 phenotype 2 and highest for phenotype 3 (Table 4, Figures 2A and S2). Fewer than half the
255 children had a BDR test done and among those, the proportion with a positive BDR test did
256 not differ across phenotypes ($p=0.406$). FeNO values differed across groups ($p<0.001$) being
257 highest among children with phenotype 4 [17.9 ppb, 95% confidence interval (CI) 15.6–19.5]

258 and lowest for children with phenotype 2 (7.0 ppb, 95% CI 5.0–17.7) (Table 4, Figure 2B).

259 Similarly, positive allergy tests differed across phenotypes ($p < 0.001$) and were more

260 common among children with phenotype 4 (70%, 95% CI 64–76), and relatively rare for

261 children with phenotype 1 (31%, 95% CI 23–41).

262 Regarding prognosis after 1 year, overall, cough was less often reported at follow-up (Figure

263 3) compared with baseline (Table 1). Children with phenotype 3 more often reported cough

264 without a cold (66%), cough more than others (52%), and cough more than 4 weeks (24%)

265 compared with children in other phenotypes (Figure 3). Night cough was more prevalent for

266 children with phenotype 2 (57%) followed by children with phenotype 3 (41%). Wheeze was

267 reported among 78 (22%) children and the proportion differed across the 4 phenotypes

268 ($p = 0.005$). Children with phenotype 4 wheezed almost 3 times more after 1 year compared

269 with children in phenotype 1.

270 **4. DISCUSSION**

271 Our study applied LCA to identify phenotypes in children who cough without wheeze. We

272 applied this method to a set of parent-reported cough-related symptoms and characteristics

273 in a clinical-based study. We identified 4 cough phenotypes with the allergic cough

274 phenotype as dominant. Upon validating the identified phenotypes, we found they differed

275 with respect to parent-reported information about family histories and comorbidities,

276 paediatric pulmonologist diagnoses, measurable traits, and respiratory prognosis 1 year

277 later.

278 **4.1 Strengths and limitations**

279 Ours is the first study identifying cough phenotypes in a clinical cohort of children by

280 applying a data-driven unsupervised learning approach to a wide range of cough symptoms

281 and characteristics. We used broad inclusion criteria—answering positively to any question
282 about cough—for our study population, which minimised the risk of missing some
283 phenotypes. In a previous population-based study, we found only a partial overlap between
284 positive answers to different cough questions, which likely reflects the existence of
285 subgroups of children with differences in underlying pathophysiology.^[37] For phenotype
286 definitions, we used only cough-related symptoms and characteristics easily collected in
287 primary care settings to make our results applicable to all healthcare settings. Lastly, we
288 used different ways to validate the 4 phenotypes, including parent-reported information,
289 paediatric pulmonologist diagnoses, measurable traits, and 1-year prognosis to help
290 ascertain clinical relevance. Our study also has some limitations. First, despite our use of a
291 data-driven approach, selecting variables to include in the model always involves some
292 degree of subjectivity. Second, our baseline questionnaire lacked information about signs
293 and symptoms of some possible aetiologies of cough, such as gastroesophageal reflux and
294 psychogenic and habit/tic cough, which thus could not serve as indicator variables to build
295 the latent class model. Third, our study population is mainly representative of German- and
296 French-speaking families in Switzerland and includes few recent immigrants. Finally, we did
297 not externally validate our findings among an independent clinical population of children—
298 an interest for future studies to determine if we identify similar phenotypes. However, we
299 are unaware of a similar study for validation.

300 **4.2 Comparison with other studies**

301 Our study is the first of its type to use LCA for identifying cough phenotypes among a clinical
302 population of children. We cannot fully compare our findings with population-based studies
303 also using LCA or similar clustering techniques to distinguish cough phenotypes.^[15, 26-28, 38]
304 We provide a summary of study designs and populations, inclusion criteria, indicator

305 variables, identified phenotypes/trajectories, and validation processes from existing studies
306 in Table S6. Spycher et al. and Weinmayr et al. included children who wheeze and used
307 mostly wheeze-related symptoms with only few questions about cough as indicator
308 variables in the LCA.^[15, 27] Spycher et al. also included physiological measurements as
309 indicator variables in the LCA.^[15] In contrast, we excluded children who wheezed, and as
310 indicator variables, we used a rich set of only cough-related questions allowing us to identify
311 more cough phenotypes and to describe them in more detail.

312 Divaret-Chauveau et al. and Rancièrè et al. investigated cough without cold and dry night
313 cough trajectories, respectively.^[28, 38] Both studies used only cough questions collected at
314 different time points to define cough trajectories/patterns, but they included children who
315 wheeze; and the children were also younger (Table S6). In an analysis stratified by presence
316 or absence of wheeze, Divaret-Chauveau et al. found physician-diagnosed asthma reported
317 among a small proportion of children in all cough trajectories (2 to 12%) even in the absence
318 of wheeze.^[28] Rancièrè et al. also reported physician-diagnosed asthma ever in all cough
319 patterns (7 to 26%) but this included children who wheeze.^[38] In our study, parent-reported,
320 physician-diagnosed asthma ever was also reported in all identified cough phenotypes, yet
321 in much higher proportions (22 to 55%). This might be explained by the difference in study
322 populations, since children visiting respiratory outpatient clinics likely present with more
323 severe respiratory problems than children from the general population.

324 **4.3 Interpretation and implication of findings**

325 Our study distinguished 4 phenotypes of cough among children. Based only on parent-
326 reported characteristics, distinctions between different phenotypes were not clear-cut, yet
327 reflect the realities and difficulties of clinical practice when trying to establish underlying

328 aetiologies of cough based on history alone with further examinations usually required.
329 Nevertheless, interesting and clinically-relevant patterns, such as cough driven by allergies
330 and upper airway pathology, correlating with several parent-reported characteristics,
331 paediatric pulmonologist diagnoses, measurable traits and prognosis, emerged from the
332 latent class model.

333 Interestingly, most children (70%) had phenotypes related to allergy (Phenotypes 3 and 4).
334 In terms of clinical implications, children who cough with allergic symptoms possibly need
335 allergy and asthma work-ups even in absence of reported wheeze. Divaret-Chauveau et al.
336 also concluded as such; they found an association between different cough trajectories and
337 asthma/allergic rhinitis.^[28] Similarly, Ranci re et al. found an association between children
338 with rising cough patterns—late and persistent coughers—and allergic comorbidity,
339 including asthma, and atopy, independent of the presence of wheeze.^[38]

340 Additionally, the relatively high proportion of children reporting wheeze at follow-up
341 (overall: 22%, range 10 to 29% for all 4 phenotypes) supports the need for further asthma
342 work-ups. Our statistical model identified specific groups of children who more often
343 develop wheeze and possibly asthma in the future. Spycher et al. also found that risk of
344 reporting wheeze at follow-up was higher among children of the persistent cough
345 phenotype compared with the transient cough phenotype (25% vs 10%).^[15] Ranci re et al.
346 found prevalence of wheeze at follow-up lowest among preschool children with infrequent
347 night cough (4%) compared with transient (8%) and rising pattern (consisting of late and
348 persistent cough, 16%).^[38] Findings from these studies and ours highlight the importance of
349 identifying subgroups of children with cough since their prognoses differ.

350

351 Another interesting finding of our study is the identification of 2 cough phenotypes
352 potentially driven by upper airway problems—1 allergic (phenotype 3) and 1 non-allergic
353 (phenotype 2). The presence of night cough and snoring, long duration of cough, and rhino-
354 conjunctivitis in phenotype 3 suggests house dust mite allergy. Children with phenotype 2
355 also had a high probability of night-time cough and snoring, yet in contrast to children with
356 phenotype 3, without an allergic component, with more frequent infections (colds,
357 pneumonia, otitis), and rarely reported dry cough. Phenotype 2 possibly represents children
358 with recurrent upper airway infections and adenoid hypertrophy or postnasal rhinorrhoea—
359 a small group (4% of children) perhaps restricted by our study population of children aged 5
360 years and older when respiratory infections become less common.^[10] This group also had
361 the lowest estimated median lung function parameters but the number of children in this
362 group was small and estimates were subject to much uncertainty.

363 The second largest group (phenotype 1: unspecific dry cough) possibly represents children
364 with the so-called *non-specific isolated cough*—a “dry cough in the absence of identifiable
365 respiratory or known aetiology.”^[39] This group of children seems to have a more transient
366 cough, as compared with the other phenotypes, their prognosis after 1 year was better with
367 less cough and less wheeze.

368 **5. CONCLUSION**

369 The 4 cough phenotypes we identified by LCA revealed interesting clinical patterns, which
370 may be helpful in clinical settings. Most children (70%) had a phenotype associated with
371 allergies. Thus, most children who cough may benefit from allergy and asthma diagnostic
372 work-ups even in absence of reported wheeze.

373 **AUTHOR CONTRIBUTIONS**

374 CK, ESLP, and MG designed and set-up the SPAC study. CK, MCM, ESLP, and MG
375 conceptualised the analysis with input from SB, KH, AJ, PL, AM, NR, and BDS. SB, KH, AJ, PL,
376 AM, NR, and CK recruited participants for the study. MCM, ESLP, and RM collected and
377 entered data. MCM performed statistical analyses. BDS and ESLP supported statistical
378 analyses. MCM drafted the manuscript with substantial input from CK. All authors
379 interpreted the data, critically reviewed the manuscript, and approved the final version of
380 the manuscript.

381

382 **ACKNOWLEDGEMENTS**

383 We thank the families who took part in the SPAC study, the research assistants (Natalie
384 Messerli, Gia Thu Ly, Labinata Gjokaj and Meret Ryser) for helping with data collection and
385 data entry, Kristin Marie Bivens, PhD (Institute of Social and Preventive Medicine, University
386 of Bern) for her editorial contribution, PedNet Bern for supporting data collection in Bern,
387 and the members of the SPAC study team.

388 SPAC study team members include D. Mueller-Suter, P. Eng, and A. Kuhn (Canton Hospital
389 Aarau, Aarau, Switzerland); U. Frey, J. Hammer, A. Jochmann, D. Trachsel, and A. Oettlin
390 (University Children's Hospital Basel, Basel, Switzerland); P. Latzin, C. Abbas, M. Bullo, O.
391 Fuchs, E. Kieninger, I. Korten, L. Krüger, B. Seyfried, F. Singer, and S. Yammine, C.de Jong
392 (University Children's Hospital Bern, Bern, Switzerland); C. Casaulta and P. Iseli (Children's
393 Hospital Chur, Chur, Switzerland); K. Hoyler (private pediatric pulmonologist, Horgen,
394 Switzerland); S. Blanchon, S. Guerin, and I. Rochat (University Children's Hospital Lausanne,
395 Lausanne, Switzerland); N. Regamey, M. Lurà, M. Hitzler, A. Clavuot, K. Hrup, and J. Stritt
396 (Canton Hospital Lucerne, Lucerne, Switzerland); J. Barben (Children's Hospital St Gallen, St

397 Gallen, Switzerland); O. Sutter (private pediatric practice, Worb, Bern, Switzerland); A.
398 Moeller, A. Hector, K. Heschl, A. Jung, T. Schürmann, L. Thanikkel, and J. Usemann
399 (University Children’s Hospital Zurich, Zurich, Switzerland); and C.E. Kuehni, C. Ardura-
400 Garcia, D. Berger, T.Krasnova, R. Makhoul, M.C. Mallet, E. Pedersen, and M. Goutaki
401 (University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland).

402 **FUNDING INFORMATION**

403 The Swiss National Science Foundation (SNF Grants: SNF 320030_182628 & SNF
404 320030_212519) funded the study. Myrofora Goutaki is funded by an SNF Ambizione
405 Fellowship (PZ00P3_185923).

406 **CONFLICT OF INTEREST**

407 MCM, ESLP, RM, AJ, MG, BDS, and CK have nothing to disclose. SB reports
408 meeting/travelling fees from OM Pharma and Novartis—all outside the submitted work. KH
409 reports personal fees from Astra Zeneca—all outside the submitted work. PL reports
410 personal fees from OM Pharma, Polyphor, Santhera, Vertex, Vifor, Sanofi Aventis, and
411 grants from Vertex—all outside the submitted work. AM reports personal fees from Vertex,
412 OM Pharma, Astra Zeneca, and grants from Vertex— all outside the submitted work. NR
413 reports personal fees from OM Pharma, Astra Zeneca, Schwabe Pharma, and Sanofi—all
414 outside the submitted work.

415 **DATA AVAILABILITY STATEMENT**

416 The data supporting our study findings are available on reasonable request from the
417 corresponding author.

418 REFERENCES

- 419 1. Chang AB, Robertson CF, Van Asperen PP, Glasgow NJ, Mellis CM, Masters IB, et al. A
420 multicenter study on chronic cough in children : burden and etiologies based on a standardized
421 management pathway. *Chest*. 2012;142(4):943-50.
- 422 2. Marchant JM, Newcombe PA, Juniper EF, Sheffield JK, Stathis SL, Chang AB. What is the
423 burden of chronic cough for families? *Chest*. 2008;134(2):303-9.
- 424 3. Shields MD, Bush A, Everard ML, McKenzie S, Primhak R. BTS guidelines: Recommendations
425 for the assessment and management of cough in children. *Thorax*. 2008;63 Suppl 3:iii1-iii15.
- 426 4. Cash H, Trosman S, Abelson T, Yellon R, Anne S. Chronic cough in children. *JAMA Otolaryngol*
427 *Head Neck Surg*. 2015;141(5):417-23.
- 428 5. De Benedictis FM, Selvaggio D, De Benedictis D. Cough, wheezing and asthma in children:
429 lesson from the past. *Pediatric Allergy and Immunology*. 2004;15(5):386-93.
- 430 6. Gao F, Gu Q-L, Jiang Z-D. Upper airway cough syndrome in 103 children. *Chinese Medical*
431 *Journal*. 2019;132(6):653-8.
- 432 7. Asilsoy S, Bayram E, Agin H, Apa H, Can D, Gulle S, et al. Evaluation of chronic cough in
433 children. *Chest*. 2008;134(6):1122-8.
- 434 8. Gedik AH, Cakir E, Torun E, Demir AD, Kucukkoc M, Erenberk U, et al. Evaluation of 563
435 children with chronic cough accompanied by a new clinical algorithm. *Ital J Pediatr*. 2015;41:73.
- 436 9. Yu X, Kong L, Jiang W, Dai Y, Wang Y, Huang L, et al. Etiologies associated with chronic cough
437 and its clinical characteristics in school-age children. *Journal of thoracic disease*. 2019;11(7):3093-
438 102.
- 439 10. Marchant JM, Masters IB, Taylor SM, Cox NC, Seymour GJ, Chang AB. Evaluation and
440 outcome of young children with chronic cough. *Chest*. 2006;129(5):1132-41.
- 441 11. Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-
442 based clinical practice guidelines. *Chest*. 2006;129(1 Suppl):260s-83s.
- 443 12. Chang AB, Oppenheimer JJ, Irwin RS. Managing Chronic Cough as a Symptom in Children and
444 Management Algorithms: CHEST Guideline and Expert Panel Report. *Chest*. 2020;158(1):303-29.
- 445 13. Morice AH, Millqvist E, Bieksiene K, Birring SS, Diczpinigaitis P, Domingo Ribas C, et al. ERS
446 guidelines on the diagnosis and treatment of chronic cough in adults and children. *The European*
447 *respiratory journal*. 2020;55(1).
- 448 14. Mori M, Krumholz HM, Allore HG. Using Latent Class Analysis to Identify Hidden Clinical
449 Phenotypes. *JAMA*. 2020;324(7):700-1.
- 450 15. Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of
451 childhood wheeze and cough using latent class analysis. *Eur Respir J*. 2008;31(5):974-81.
- 452 16. Ross MK, Eckel SP, Bui AAT, Gilliland FD. Asthma clustering methods: a literature-informed
453 application to the children's health study data. *J Asthma*. 2022;59(7):1305-18.
- 454 17. Spycher BD, Silverman M, Kuehni CE. Phenotypes of childhood asthma: are they real? *Clin*
455 *Exp Allergy*. 2010;40(8):1130-41.
- 456 18. Lee E, Lee SH, Kwon JW, Kim YH, Yoon J, Cho HJ, et al. Persistent asthma phenotype related
457 with late-onset, high atopy, and low socioeconomic status in school-aged Korean children. *BMC*
458 *Pulm Med*. 2017;17(1):45.
- 459 19. Brew BK, Chiesa F, Lundholm C, Örtqvist A, Almquist C. A modern approach to identifying
460 and characterizing child asthma and wheeze phenotypes based on clinical data. *PLoS One*.
461 2019;14(12):e0227091.
- 462 20. Oksel C, Granell R, Haider S, Fontanella S, Simpson A, Turner S, et al. Distinguishing Wheezing
463 Phenotypes from Infancy to Adolescence. A Pooled Analysis of Five Birth Cohorts. *Ann Am Thorac*
464 *Soc*. 2019;16(7):868-76.
- 465 21. Fitzpatrick AM, Bacharier LB, Guilbert TW, Jackson DJ, Szeffler SJ, Beigelman A, et al.
466 Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and
467 Utility in Prediction of Future Exacerbation. *J Allergy Clin Immunol Pract*. 2019;7(3):915-24.e7.

- 468 22. Fitzpatrick AM, Bacharier LB, Jackson DJ, Szeffler SJ, Beigelman A, Cabana M, et al.
469 Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class
470 Analysis and Association with 1-Year Outcomes. *J Allergy Clin Immunol Pract*. 2020;8(8):2617-27.e4.
471 23. Ferrante G, Fondacaro C, Cilluffo G, Dones P, Cardella F, Corsello G. Identification of
472 bronchiolitis profiles in Italian children through the application of latent class analysis. *Ital J Pediatr*.
473 2020;46(1):147.
474 24. Niu H, Chang AB, Oguoma VM, Wang Z, McCallum GB. Latent class analysis to identify clinical
475 profiles among indigenous infants with bronchiolitis. *Pediatr Pulmonol*. 2020;55(11):3096-103.
476 25. Petrarca L, Nenna R, Di Mattia G, Frassanito A, Castro-Rodriguez JA, Rodriguez Martinez CE,
477 et al. Bronchiolitis phenotypes identified by latent class analysis may influence the occurrence of
478 respiratory sequelae. *Pediatr Pulmonol*. 2022;57(3):616-22.
479 26. Spycher BD, Silverman M, Pescatore AM, Beardsmore CS, Kuehni CE. Comparison of
480 phenotypes of childhood wheeze and cough in 2 independent cohorts. *J Allergy Clin Immunol*.
481 2013;132(5):1058-67.
482 27. Weinmayr G, Keller F, Kleiner A, du Prel JB, Garcia-Marcos L, Batllés-Garrido J, et al. Asthma
483 phenotypes identified by latent class analysis in the ISAAC phase II Spain study. *Clin Exp Allergy*.
484 2013;43(2):223-32.
485 28. Divaret-Chauveau A, Mauny F, Hose A, Depner M, Dalphin ML, Kaulek V, et al. Trajectories of
486 cough without a cold in early childhood and associations with atopic diseases. *Clin Exp Allergy*. 2022.
487 29. Pedersen ESL, de Jong CCM, Ardura-Garcia C, Barben J, Casaulta C, Frey U, et al. The Swiss
488 Paediatric Airway Cohort (SPAC). *ERJ Open Res*. 2018;4(4).
489 30. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). *Am Rev Respir*
490 *Dis*. 1978;118(6 Pt 2):1-120.
491 31. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of
492 Asthma and Allergies in Childhood (ISAAC): rationale and methods. *Eur Respir J*. 1995;8(3):483-91.
493 32. Clifford RD, Radford M, Howell JB, Holgate ST. Prevalence of respiratory symptoms among 7
494 and 11 year old schoolchildren and association with asthma. *Arch Dis Child*. 1989;64(8):1118-25.
495 33. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO
496 growth reference for school-aged children and adolescents. *Bull World Health Organ*.
497 2007;85(9):660-7.
498 34. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference
499 values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir*
500 *J*. 2012;40(6):1324-43.
501 35. Araya-Cloutier CV, J; Van de Schans, M; Hageman, J; Schaftenaar, G. ATS/ERS
502 recommendations for standardized procedures for the online and offline measurement of exhaled
503 lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med*.
504 2005;171(8):912-30.
505 36. Weller BEB, N.K; Faubert, S.J. Latent Class Analysis: A Guide to Best Practice. *Journal of Black*
506 *Psychology*. 2020;46(4):287-311.
507 37. Mallet MCM, R; Pedersen, E.S.L; Ardura-Garcia, C; Gaillard, E.A; Latzin, P; Moeller, A; Kuehni,
508 C.E. Prevalence of childhood cough in epidemiological studies depends on the question used:
509 findings from two population-based studies. *Swiss Med Wkly*. 2023; 153:40044.
510 38. Rancière F, Nikasinovic L, Momas I. Dry night cough as a marker of allergy in preschool
511 children: the PARIS birth cohort. *Pediatr Allergy Immunol*. 2013;24(2):131-7.
512 39. Chang AB. Chronic non-specific cough in children. *Paediatrics and Child Health*.
513 2008;18(7):333-9.

514


Tables and Figures

Table 1: Characteristics of study population included in the latent class analysis at baseline (N=531)

	N (%)
Sociodemographic and environmental exposure	
Male sex	314 (59)
Age, years (median, IQR)	11 (8–13)
Overweight or obesity based on BMI z-scores (N=521)	125 (24)
Swiss nationality	436 (82)
Parental highest education level	
Maternal tertiary (N=511)	149 (29)
Paternal tertiary (N=504)	203 (40)
Exposure to tobacco smoke (N=498)	142 (29)
Parental history	
Asthma or asthma inhaler use	191 (36)
Hay fever	247 (47)
Chronic cough	73 (14)
Comorbidities ever in life	
Previous wheeze	223 (42)
Physician-diagnosed asthma	245 (46)
Hay fever	222 (42)
Physician-diagnosed eczema	112 (21)
Cough symptoms and characteristics during the past 12 months	
Dry night cough	276 (52)
Cough without a cold	446 (84)
Cough more than others	289 (54)
Cough duration > 4 weeks	215 (40)
Cough duration > 2 months	79 (15)
Cough type	
Mostly dry	253 (48)
Mostly wet	53 (10)
Both dry and wet	221 (42)
Cough triggered by any aero-allergens (pollen, house dust, animals)	318 (60)
Other symptoms in the past 12 months	
Number of colds \geq 7/year	61 (11)
Otitis media	47 (9)
Pneumonia	31(6)
Rhino-conjunctivitis	195 (37)
Snoring (without cold/almost always)	186 (35)

IQR: Interquartile range, BMI: Body Mass Index, we calculated BMI z-scores using reference values from the World Health Organisation; Parental history, comorbidities ever, cough and other symptoms are parent-reported.

Figure 1: Estimated class sizes (in brackets)* and estimated probabilities of cough-related symptoms and characteristics of the four-class model identified by latent class analysis based on the lowest Akaike Information Criterion (N=531)



*The width of the lines represents the size of the classes, i.e. the proportion of children in the different classes. The estimated probabilities which can take values from 0 to 1 and represent the probability of answering 'yes' for the dichotomous indicators variables (frequent colds ≥ 7 , pneumonia, otitis media, night cough, rhino-conjunctivitis, snoring, mostly dry cough, cough > 2 months) for each of the 4 classes, while the estimated mean which can take values from 0 to 3 represents the average number of allergic cough triggers for each of the 4 classes.

Table 2: Socio-demographic characteristics, parental smoking, family history, and comorbidities for the 4 cough phenotypes (N=531)

Class	1		2		3		4		p-value
	Unspecific dry cough		Non-allergic infectious and night cough with snoring and otitis		Allergic dry night cough with snoring		Allergic cough		
Class description	(N=145)		(N=18)		(N=45)		(N=323)		
	N	% (95%CI)	N	% (95%CI)	N	% (95%CI)	N	% (95%CI)	
Sex (Male)	78	54 (46–62)	13	72 (48–88)	24	53 (39–67)	199	62 (56–67)	0.218
Age, years (median)	145	10 (9–11)	18	7 (7–10)	45	9 (8.0–10)	323	11 (11–12)	<0.001*
Swiss nationality	125	86 (80–91)	15	83 (59–95)	29	64 (50–77)	267	83 (78–86)	0.010
Parental tertiary education									
Maternal	43	31 (23–39)	4	24 (9–49)	20	44 (31–59)	82	27 (22–32)	0.092
Paternal	49	35 (27–43)	4	27 (10–53)	20	45 (31–60)	130	43 (37–48)	0.239
Parental smoking	38	29 (22–37)	6	33 (16–57)	12	27 (16–42)	86	28 (23–34)	0.966
Parental history									
Asthma	41	28 (22–36)	6	33 (16–57)	11	24 (14–39)	133	41 (36–47)	0.017
Hay fever	48	33 (26–41)	9	50 (28–72)	18	40 (27–55)	172	53 (48–59)	0.001
Chronic cough	19	13 (9–20)	2	11 (3–35)	6	13 (6–27)	46	14 (11–19)	0.973
Comorbidities ever									
Previous wheeze	37	26 (19–33)	5	28 (12–52)	8	18 (9–32)	173	54 (48–59)	<0.001
Physician-diagnosed asthma ever	51	35 (28–43)	4	22 (9–47)	12	27 (16–41)	178	55 (50–60)	<0.001
Hay fever	13	9 (5–15)	1	6 (1–31)	14	31 (19–46)	194	60 (55–65)	<0.001
Eczema	18	12 (8–19)	3	17 (5–41)	8	18 (9–32)	83	26 (21–31)	0.011

p-values calculated using chi-square test, *p-value calculated using Kruskal-Wallis test;

CI: confidence interval

Table 3: Diagnoses given by physicians to children in the 4 cough phenotypes (N=531)

Class		1	2	3	4	
Class description	Total	Unspecific dry cough	Non-allergic infectious and night cough with snoring and otitis	Allergic dry night cough with snoring	Allergic cough	
	(N=531)	(N=145)	(N=18)	(N=45)	(N=323)	
	N (%)	N (%)	N (%)	N (%)	N (%)	p-value
Confirmed asthma ¹	204 (38)	38 (26)	1 (6)	9 (20)	156 (48)	<0.001
Any confirmed or suspected asthma/asthma-like diagnosis ²	370 (70)	80 (55)	8 (44)	22 (49)	260 (81)	<0.001
Any confirmed chronic cough diagnosis ³	73 (14)	29 (20)	4 (22)	15 (33)	25 (8)	<0.001
Any confirmed or suspected chronic cough diagnosis ⁴	103 (19)	41 (28)	7 (39)	20 (44)	35 (11)	<0.001
Any confirmed exercise-related problem ⁵	22 (4)	10 (7)	2 (11)	1 (2)	9 (3)	0.059*
Any confirmed or suspected exercise-related problem ⁶	46 (9)	20 (14)	2 (11)	2 (4)	22 (7)	0.063*
Any confirmed or suspected chronic snoring problem ⁷	24 (5)	7 (5)	2 (11)	1 (2)	14(4)	0.453*
Confirmed rhinitis/rhinoconjunctivitis	213 (40)	11 (8)	3 (17)	15 (33)	184 (57)	<0.001
Confirmed allergic sensitisation/atopy	351 (66)	48 (33)	8 (44)	28 (62)	267 (83)	<0.001

Note: A child can have multiple diagnosis. *p*-values calculated using chi-square test **p*-value calculated using Fisher's exact test

¹ *confirmed* diagnosis of asthma (chronic asthma)

² *confirmed or suspected* diagnosis of asthma (episodic asthma, chronic asthma, exercise-induced asthma) and asthma-like diagnosis (wheeze, recurrent bronchitis, bronchial hyperreactivity, exercise-induced wheeze)

³ *any confirmed* diagnosis of chronic cough, including recurrent cough of unknown aetiology, increased vulnerability to viral infections, post infectious cough, psychogenic cough, chronic obstructive rhinopathy with posterior rhinorrhoea /postnasal drip, cough hypersensitivity syndrome, protracted bacterial bronchitis, gastroesophageal reflux disease

⁴ *any confirmed or suspected* diagnosis of chronic cough, including recurrent cough of unknown aetiology, increased vulnerability to viral infections, post infectious cough, psychogenic cough, chronic obstructive rhinopathy with posterior rhinorrhoea /postnasal drip, cough hypersensitivity syndrome, protracted bacterial bronchitis, gastroesophageal reflux disease

⁵ *any confirmed* exercise-related problems, including dysfunctional breathing, hyperventilation syndrome, stridor, sighing, vocal cord dysfunction, induced laryngeal obstruction, deconditioning

⁶ *any confirmed or suspected* exercise-related problem: dysfunctional breathing, hyperventilation syndrome, stridor, sighing, vocal cord dysfunction, induced laryngeal obstruction, deconditioning


⁷ *any confirmed or suspected* chronic snoring problem, including adenoid hypertrophy, tonsil hypertrophy, obstructive sleep apnea, unspecific snoring

Table 4: Comparison of objective features and physiological measurements based on the 4 identified cough phenotypes

Class	1		2		3		4		
Class description	Unspecific dry cough		Non-allergic infectious and night cough associated with snoring and otitis		Allergic dry night cough with snoring		Allergic cough		
	(N=145)		(N=18)		(N=45)		(N=323)		
	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	p-value
BMI based on z-scores									
Overweight or obese (N=521)	30	21 (15–28)	2	22 (9–47)	6	14 (6–28)	85	27 (22–32)	0.199
Spirometry parameters									
FEV1 z-score, median (N=451)	125	-0.37(-0.59– -0.10)	16	-0.18 (-1.58–0.71)	41	0.11(-0.21–0.68)	269	-0.37 (-0.50– -0.24)	0.022*
FVC z-score, median (N=440)	125	-0.26 (-0.52–0.01)	16	-0.36 (-1.55–1.07)	38	0.03 (-0.22–0.34)	261	-0.15 (-0.27–0.02)	0.800*
FEV1/FVC z-score, median (N=436)	122	-0.51 (-0.82–0.03)	16	-0.83 (-1.81–0.26)	38	0.18 (-0.26–0.93)	260	-0.41 (-0.53– -0.27)	0.003*
FEF25-75 z-score, median (N=316)	94	-0.86 (-1.28– -0.52)	11	-1.01 (-2.40– -0.02)	25	-0.06 (-0.75–0.51)	186	-0.75 (-0.89– -0.54)	0.023*
Bronchodilator response test									
%FEV1 bronchodilator increase, median (N=239)	73	5 (3–6)	10	10 (-3 -21)	14	3 (-1–6)	142	7 (5–8)	0.183*
Positive bronchodilator reversibility [§] (N=239)	13	18 (11–28)	4	40 (16–70)	2	14 (4–43)	28	20 (14–27)	0.406 [§]
FeNO									
High FeNO* (N=479)	23	18 (12–26)	3	20 (7–47)	11	26 (15–41)	121	41 (35–47)	<0.001
FeNO ppb [°] , median (N=450)	116	11.0 (10.0–12.0)	13	7.0 (5.0–17.7)	37	12.8 (9.6–17.7)	284	17.9 (15.6–19.5)	<0.001*
Allergy tests[¶]									
Any allergy test positive (N=353)	29	31 (23–41)	7	54 (28–78)	18	56 (39–72)	151	70 (64–76)	<0.001
Total number of positive test, median (N=353)	93	0 (0–0)	13	1 (0–1)	32	1 (0–2)	215	2 (1.6–2)	<0.001*

CI: confidence interval; BMI: body mass index; we calculated BMI z-scores using reference values from the World Health Organisation; FeNO: Fractional exhaled nitric oxide, [§]Bronchodilator reversibility defined as an increase in FEV1 of 12% after the use of a short acting beta-agonist (SABA), ⁺ Definition of high FeNO depended on technique used and specified cut-offs for each centre and excluding FeNO of bad quality [°] Including only those that performed an online measurement of FeNO and excluding those with a bad FeNO quality; [¶]include positive skin prick test or specific IgE, *p*-value calculated using chi-square test, ^{*}*p*-value calculated using Kruskal-Wallis test; [&]*p*-value calculated using Fisher's exact test

Figure 2 (A): Distribution of spirometry parameters FEV1/FVC z-score (N=436) and **(B)** Distribution of FeNO values based on the 4 identified cough phenotypes (N=450)



FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; FeNO: Fractional Exhaled Nitric Oxide; ppb: parts per billion; include FeNO values measured using the online method


Class 1: Unspecific dry cough

Class 2: Non-allergic infectious and night cough with snoring and otitis

Class 2: Allergic dry night cough with snoring

Class 4: Allergic cough

Figure 3: Prognostic outcomes after 1 year for the 4 cough phenotypes



Class 1: Unspecific dry cough

Class 2: Non-allergic infectious and night cough with snoring and otitis

Class 3: Allergic dry night cough with snoring

Class 4: Allergic cough